Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial

INTRODUCTION: Adding neurokinin-1 receptor antagonist (NK(1)RA) to 5-hydroxytryptamine-3 receptor antagonist and dexamethasone (DEX) improved carboplatin (CBDCA)-induced chemotherapy-induced nausea and vomiting (CINV) in patients with thoracic cancer. NK(1)RAs with high-drug cost are raising medical...

Descripción completa

Detalles Bibliográficos
Autores principales: Iihara, Hirotoshi, Shimokawa, Mototsugu, Gomyo, Takenobu, Fujita, Yukiyoshi, Yoshida, Tsutomu, Funaguchi, Norihiko, Minato, Koichi, Kaito, Daizo, Osawa, Tomohiro, Yamada, Momoko, Hirose, Chiemi, Suzuki, Akio, Ohno, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615793/
https://www.ncbi.nlm.nih.gov/pubmed/31278102
http://dx.doi.org/10.1136/bmjopen-2018-028056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615793/
https://www.ncbi.nlm.nih.gov/pubmed/31278102
http://dx.doi.org/10.1136/bmjopen-2018-028056

Ejemplares similares